Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1011820200610010042
Investigative and Clinical Urology
2020 Volume.61 No. 1 p.42 ~ p.50
Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study
Park Hong-Zoo

Lee Sang-Wook
Song Gee-Hyun
Kang Tae-Wook
Jung Jae-Hung
Chung Hyun-Chul
Kim Sung-Jin
Park Jong-Yeon
Shin Tae-Young
Kim Jeong-Hyun
Abstract
Purpose: To evaluate the clinical utility of percentage of serum prostate-specific antigen (proPSA) to free PSA (%p2PSA) and the prostate health index (PHI) for predicting aggressive pathological outcomes of radical prostatectomy (RP) in Korean males.

Materials and Methods: This prospective observational multicenter study included 160 Korean males who consecutively underwent RP. The predictive utility of preoperative %p2PSA and PHI for predicting the following pathological outcomes of RP including pT3 disease, pathologic Gleason sum ¡Ã7, and Gleason sum upgrading was investigated using multivariate and decision-curve analyses.

Results: The PHI and %p2PSA levels were significantly higher in patients with pT3 disease, pathologic Gleason sum ¡Ã7, and Gleason sum upgrading. On univariate analysis, PHI was an accurate predictor of pT3 disease, pathologic Gleason sum ¡Ã7, and Gleason sum upgrading. Multivariate and decision curve analyses revealed that inclusion of PHI to a base multivariate model including total PSA, percentage free PSA, PSA density, percentage of positive biopsy core, biopsy Gleason sum, and clinical stage factors significantly increased its predictive accuracy; %p2PSA showed a similar result. However, PHI was a more valuable predictor of pathological outcomes of RP.

Conclusions: This study revealed PHI and %p2PSA as preoperative biomarkers of pathological outcomes in Korean males who underwent RP for prostate cancer.
KEYWORD
Pathology, Prostatectomy, Prostatic neoplasms
FullTexts / Linksout information
 
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø